Exchange & Returns Information
Review Details
(26)
| Drug Type | Original |
|---|---|
| Active Ingredient | SEMAGLUTIDE |
| Strength | 1.7MG |
| Manufacturer | NOVO NORDISK |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 1 PEN | $ 410.00 | $ 410.00 |
$ 344.40
Apply WEGO26 (-16%)
You save $ 65.60
|
||
| 2 BOXES - 2 PENS | $ 324.50 |
21% $ 820.00
$ 649.00
|
$ 545.16
Apply WEGO26 (-16%)
You save $ 103.84
|
||
| ★ Best Value 3 BOXES - 3 PENS | $ 253.00 |
38% $ 1,230.00
$ 759.00
|
$ 637.56
Apply WEGO26 (-16%)
You save $ 121.44
|
Reference information will be available soon.
Wegovy 1.7mg Flextouch Pen is a once-weekly subcutaneous injection containing semaglutide, a long-acting GLP-1 receptor agonist developed for chronic weight management. This 1.7mg dose represents the penultimate stage in Wegovy’s structured titration schedule, allowing the patient’s body to adapt to higher hormone concentrations before reaching the full maintenance dose of 2.4mg. By activating GLP-1 receptors in key metabolic centers—pancreas, brain, and gut—semaglutide enhances insulin secretion (in a glucose-dependent manner), inhibits glucagon release, and delays gastric emptying. These effects collectively suppress appetite, increase satiety, and facilitate sustained fat loss. Although semaglutide is used off-label for type 2 diabetes, Wegovy is indicated strictly for weight control, not for glycemic management.
- DIET (Metabolic Weight Control) > Designed to support adults with obesity (BMI ≥30 kg/m²) or overweight status (BMI ≥27 kg/m² with comorbidities) in achieving long-term weight reduction. Wegovy’s 1.7mg stage is essential for preparing the body to tolerate the full 2.4mg dose while maintaining effective appetite suppression and fat metabolism support. - DIABETES (GLP-1 Receptor Agonists) > While semaglutide’s mechanism may benefit blood sugar regulation, Wegovy is not approved for treating type 2 diabetes. Any glycemic effects observed during Wegovy use are incidental and considered off-label. Patients with concurrent obesity and diabetes must consult physicians before using semaglutide outside approved indications.
Semaglutide mimics endogenous GLP-1, a gut-derived hormone that plays a pivotal role in glucose and appetite regulation. Upon binding to GLP-1 receptors, it enhances insulin release (only when glucose levels are elevated), suppresses postprandial glucagon, and slows gastric emptying—helping extend feelings of fullness. It also impacts appetite centers in the hypothalamus, reducing cravings and caloric intake without causing jitteriness or cardiovascular strain. The 1.7mg dose continues to build on prior weekly increments, ensuring steady metabolic adaptation while minimizing gastrointestinal side effects common during dose escalation.
→ Wegovy Chronic Weight Management Schedule: - Week 1–4: 0.25 mg SC once weekly - Week 5–8: 0.5 mg SC once weekly - Week 9–12: 1.0 mg SC once weekly - Week 13–16: 1.7 mg SC once weekly *(This product applies here)* - Week 17+: 2.4 mg SC once weekly (maintenance phase) → Adjustment Protocol: - If patient cannot tolerate 2.4 mg: maintain 1.7 mg/week for up to 4 additional weeks, then retry 2.4 mg - If still not tolerated, discontinue therapy - Dose increases can be delayed by 4 weeks to improve tolerability → Indication Criteria: - Adults with BMI ≥30 kg/m² - Or BMI ≥27 kg/m² with weight-related conditions such as hypertension, dyslipidemia, or insulin resistance → Administration: - Inject once weekly (same day each week) subcutaneously - Rotate between abdomen, thigh, and upper arm - Do not use with other GLP-1 receptor agonists or semaglutide products → Off-Label Glycemic Use (Not Wegovy Indication): - Although 1.7mg is not a standard dose in diabetes protocols, some clinicians may use it off-label for patients requiring enhanced satiety and modest glycemic support - These uses must be individualized and physician-supervised
Keep refrigerated (2–8°C) until use. Do not freeze. Once opened, pens may be stored at room temperature (below 30°C) for up to 28 days. Protect from light and heat. Store safely out of reach of children.
Nausea, vomiting, diarrhea, and constipation are among the most common side effects, particularly during dose titration. These symptoms are usually transient and improve over time. Other reported effects include fatigue, indigestion, and injection site reactions. Serious but rare events include pancreatitis, gallstones, and renal dysfunction. Patients with a history of pancreatitis or medullary thyroid carcinoma should avoid semaglutide-based products. Seek immediate medical attention for signs of severe abdominal pain, jaundice, or persistent vomiting.
Being on this medication has taught me the power of consistency, and that's what I get from this service. My fourth pen, the 1.7mg dose, arrived just as punctually and professionally as the first. There's no stress or uncertainty, which is so important when you're trying to build and maintain healthy habits. The product is always authentic and in perfect condition. I couldn't be happier with the service.
Wegovy has helped me tune into my body's actual hunger signals. It's been very empowering.
Reordering is always a breeze, and the refrigerated shipping is consistently perfect.
For anyone on a long-term prescription journey, this site's reliability is a huge asset.
ฉันใช้ Wegovy มาหลายเดือนแล้ว และการมีร้านขายยาออนไลน์ที่เชื่อถือได้เป็นสิ่งสำคัญมาก การสั่งซื้อปากกาขนาด 1.7 มก. นั้นง่ายดาย และจัดส่งมาในบรรจุภัณฑ์ควบคุมอุณหภูมิอย่างดีเสมอ การใช้ยานี้ช่วยให้ฉันปรับเปลี่ยนวิถีชีวิตและมีสุขภาพที่ดีขึ้นได้จริงๆ มันเป็นเครื่องมือที่ช่วยเปลี่ยนแปลงชีวิต และบริการจากร้านนี้ก็ยอดเยี่ยมไร้ที่ติค่ะ
No combo deals available at the moment.
